Home » News » Drug Sponsors » Axcan acquires Mpex

Axcan acquires Mpex

Thursday, April 14, 2011

Two pharmaceutical companies, Mpex and Axcan, have entered into an agreement in which Axcan will acquire all of the outstanding shares of Mpex and its lead product candidate, Aeroquin.  An aerosol formulation of levofloxacin, Aeroquin is currently in phase III clinical trials for the treatment of pulmonary infections in patients with cystic fibrosis.

All assets not associated with Aeroquin, including financial and human resources, will be taken from Mpex and used to form a new company.  The new company will remain in San Diego and the former personnel of Mpex will continue to lead the Aeroquin clinical development program in collaboration with Axcan.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!